France finally has a full budget for 2026, ending months of stasis, and providing a degree of certainty to industry. However, especially for pharma, continual price cuts threaten the sustainability of France as an investment destination, although the reindustrialisation incentives contained with the ‘France 2030’ plan are leading to an unprecedented life sciences manufacturing boom.
Finance: EUR 5 billion in health spending cuts, long-term care focus, hospital efficiency, and tackling medical deserts
On 2nd February 2026, Prime Minister Sébastien Lecornu’s minority government was finally able to pass a full budget for the year after surviving repeated no-confidence motions. As Lecornu’s government lacks a majority, both the full budget and the Social Security & Healthcare Bill 2026 (PLFSS 2026) were pushed through under Article 49.3 of the Constitution, which allows adoption without a vote unless a no-confidence motion passes.
The budget aims to bring France’s overall fiscal deficit down to 5 percent of GDP in 2026, from an estimated 5.4 percent in 2025. Thanks to political concessions, this is a less ambitious target than the government’s initial aim of 4.7 percent.
PLFSS 2026 aims to reduce France’s massive social security deficit from EUR 23 billion in 2025 to EUR 17.4 billion in 2026 and achieve budget balance by 2029. As well as doubling the amount which patients pay for healthcare co-payments and deductibles, the Bill proposes stronger regulation of what the government sees as over-profitable health sectors (including radiology and dialysis), as well as drug price cuts worth EUR 1.6 billion (EUR 1.4 billion for medicines, 0.2 billion for devices).
In a push to modernise and rationalise healthcare spending, the Bill includes plans to redesign long-term illness coverage with a focus on severe cases and an expansion of preventive care pathways.
Elsewhere, EUR 2.3 billion has been earmarked for improving the efficiency of the country’s hospitals, while a new ‘France Santé’ network of 5,000 local health centres aims to ensure that every French resident can reach a medical service in under 30 minutes.
Additionally, the Bill supports grouped hospital tenders for specific categories of medicines; an attempt to drive prices down and increase generic and biosimilar competition.
Continuing Pricing Pressures & Access Delays
The French pharmaceutical industry already faces some of the lowest list prices in Europe and severe access delays. Especially for industry sponsors operating in high-spend therapeutic areas like oncology and rare diseases, 2026 is set to be another tough year, with less headroom for new launches and increased scrutiny of their profitability.
Industry leaders warn that while France’s reliance on annual price cuts may yield short-term savings, it erodes the fiscal predictability required for reinvestment in R&D and local manufacturing, undermining the goals of the EUR 54 billion France 2030 investment plan.
As reporting from G5 Santé shows, French drug prices are already 30 percent lower than in Germany and 15 percent lower than the EU average. Successive price cuts have weakened local production and led to 40 percent of treatments authorised in Europe remaining inaccessible in France.
Moreover, France is a market beset by access delays. A dense web of regulatory, pricing, and reimbursement negotiations slows the process, leading to an average time between marketing authorisation and reimbursement/launch of 523 days (compared to 219 in Austria, 204 in Switzerland, and just 52 in Germany), according to the 2025 Patients W.A.I.T. (Waiting to Access Innovative Therapies) Indicator, produced by IQVIA and EFPIA.
There is an international element to this challenging situation too. The US government’s threats to align domestic drug prices with the lowest prices charged in Europe risk exacerbating an already precarious situation. If France becomes a low-ceiling reference country for the US, companies may delay or defer launching in France to avoid depressing prices elsewhere.
This is already playing out within Europe’s borders, where countries like Poland, the Czech Republic, Hungary, and Slovakia explicitly use France as one of their reference pricing countries. In recent years, global firms including AstraZeneca, Vertex, and Novartis have all delayed or withdrawn product listings in France due to its low list prices and their knock-on effects elsewhere.
France 2030: Strategic Reindustrialisation
France 2030 is the French government’s flagship EUR 54 billion investment plan, launched in October 2021 by Emmanuel Macron. It is designed to reindustrialise France, accelerate strategic technologies, and secure economic sovereignty over the next decade.
Health represents one of the programme’s most heavily funded strategic domains, with more than EUR 7.5 billion directed toward life sciences and EUR 800 million specifically earmarked for biotherapies and biomanufacturing. The ambition is explicit: reduce dependence on imported medicines, reinforce strategic production capacity, and position France as a European leader in next-generation therapies.
In practical terms, the programme is already reshaping the landscape. France is currently experiencing its biggest pharmaceutical manufacturing boom in decades, with global giants like Novo Nordisk, Sanofi, and Pfizer collectively committing over EUR 4 billion in new investments since 2023
Around 50 essential medicines have been identified for relocation or reinforcement of domestic production, while 42 biotherapy production projects are receiving active state support. The objective is to increase local output from roughly 10 percent of biomedicines used in France today to around 60 domestically produced products by 2030.
Crucially, the strategy extends beyond factory construction. Five bio-clusters dedicated to oncology, gene therapy, neuroscience, immunology, and infectious diseases are designed to close France’s longstanding translation gap between academic discovery and industrial scale. Major campuses such as the Paris-Saclay Cancer Cluster, eventually spanning 100,000 square metres, aim to accelerate start-ups toward Phase II and connect them early to clinical infrastructure and capital.
What distinguishes France 2030 is the integration of industrial policy with pricing and sovereignty mechanisms. Domestic production can attract pricing recognition of up to 15 percent under CEPS methodology, embedding localisation directly into reimbursement logic.
Combined with tax reductions and decarbonisation incentives, the strategy signals a deliberate pivot: from being primarily a research powerhouse, with 21 percent of its biotech pipeline in rare diseases and around a quarter in oncology, to becoming a fully integrated innovation-to-manufacturing ecosystem.
Industry leaders are, however, warning of eroding competitiveness – with France slipping to sixth place in Europe for pharma exports and ninth for trade balance, and likely posting its first sector trade deficit after years of surplus.
